The Impact of TP53 Mutations and Use of the TP53Mutation-Reactivating Agent APR-246 on Metastatic Castrate-Sensitive Prostate Cancer

T. Hoang,P. Sutera,T. Nguyen, J. H. Chang, S. Jagtap, Y. Song,A. Shetty,D. D. Chowdhury, A. Chan,F. A. A. Carrieri, D. Song,T. L. DeWeese, A. Lafargue,K. Van der Eecken, F. Bunz, P. Ost,P. T. Tran,M. P. Deek

International journal of radiation oncology, biology, physics（2023）

引用 0|浏览7

暂无评分

摘要

DN TP53 mutations were associated with poorer survival outcomes for mCSPC patients. DN TP53 mutations also promoted prostate cancer pro-metastatic behaviors in vitro, which was effectively counteracted by APR-246, making it a promising treatment option that should be explored further in early-phase clinical studies.

查看译文

关键词

tp53 mutations,prostate cancer,mutation-reactivating,castrate-sensitive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要